Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up Study to Evaluate the Safety and Efficacy in Patients Who Have Ever Received Lentiviral-based Gene-edited Immune Cell Therapy

NCT05377307 is registered in ClinicalTrials.gov with Pell Bio-Med Technology Co., Ltd. as lead sponsor.

NCT NCT05377307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05377307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up Study to Evaluate the Safety and Efficacy in Patients Who Have Ever Received Lentiviral-based Gene-edited Immune Cell Therapy
Lead sponsor
Pell Bio-Med Technology Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
March 31, 2023
Completion date
December 31, 2037
Enrollment
49 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma grade 3a, follicular lymphoma grade 3b, large b-cell lymphoma, primary mediastinal large b cell lymphoma